BOSTON, May 23, 2017 /PRNewswire/ -- This year at the 2017 Bio-IT World Conference & Expo, Deloitte will be showcasing the latest updates to its ConvergeHEALTH suite of life sciences end-to-end evidence lifecycle management solutions, as well as hosting a series of panel discussions with life sciences innovators. Amgen, which was selected as a finalist for the Bio-IT World Best Practices Award, will also be participating on one of the Deloitte panels at the conference discussing the impact of its Translational Research Information Platform (TRIP).
At the conference, Deloitte will debut the latest updates to its ConvergeHEALTH Miner™ product suite, which helps life science companies support their evidence strategies by providing enterprise data management and analytics capabilities for information generated throughout their evidence lifecycle from translational research to clinical trials to real world evidence (RWE). Recent survey results from Deloitte's industry benchmark survey on RWE highlight the importance of executing against the end-to-end evidence imperative. More than 50 percent of life sciences innovators indicated that they are investing in their RWE programs to significantly increase their capability in this space.
"The shift toward value-based, personalized health care, means life sciences innovators must think differently about their end-to-end evidence management strategies and operating models" said Brett Davis, principal, Deloitte Consulting LLP and general manager of ConvergeHEALTH by Deloitte. "Innovators need an end-to-end approach to leveraging data, evidence, and knowledge assets that breaks down traditional siloes and fosters evidence-driven decision making across discovery, development and commercialization."
To support this imperative, Deloitte is announcing major releases to the ConvergeHEALTH Miner platform including Research Trust™ Big Data Edition, Data Asset Explorer™ and Cohort Insight™, all of which provide life sciences companies with opportunities to improve their end-to-end evidence management strategies.
"Big data technologies and linked patient data sets are unlocking new opportunities for our life sciences clients to achieve business model innovations across the pharmaceutical value chain," said Dan Housman, managing director, Deloitte Consulting LLP and CTO of ConvergeHEALTH by Deloitte. "Our new releases to the ConvergeHEALTH Miner suite were built to overcome scale, agility, and open collaboration challenges we have identified with our clients while pursuing diverse use cases including biomarker discovery, personalized therapy pathways, proactive safety signal detection, physician network analysis and value based contract modeling."
Deloitte will host a number of panel discussions and presentations with industry leaders throughout the conference. Two are:
"Data, Ecosystems and Outcomes using Evidence from Bench to Bedside and Back," Wednesday, May 24, 12:40 p.m.; Track 8: Clinical and Translational Informatics Luncheon panel presentation on secondary use of data with executives from Takeda, Celgene, Amgen and moderated by Brett Davis from Deloitte Consulting LLP.
"Case Study: The Observational Health Data Sciences & Informatics Collaborative," Thursday, May 25, 2:30 p.m.; Track 4: Software Applications & Services, moderated by Kristin Feeney, senior data scientist, Deloitte Consulting LLP.
Best Practice Awards
On Thursday, May 25, Bio-IT World will announce the winner of its Best Practices Award, honoring excellence in bioinformatics, basic and clinical research and IT frameworks for biology and drug discovery. Amgen with Deloitte was selected as a finalist for the Bio-IT World Best Practices Award for their collaborative work in pioneering TRIP.
TRIP is an on-demand cloud database of data that provides researchers with extensible yet easy-to-use data and analytics as well as a visualization portal. Today, many of their translational research needs are addressed in this cloud-based information integration platform that houses over 400 clinical datasets, over 1,600 nonclinical studies, almost 3 million bio-specimens, and increasing amounts of genomics data. TRIP is able to deliver data-driven answers to scientific questions and has already resulted in improved research collaboration, accelerated hypothesis generation, and increased understanding of disease mechanisms which is why the Amgen and Deloitte team was recognized as a finalist for this award.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including 80 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to deliver measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/deloitte-debuts-convergehealth-evidence-lifecycle-management-solutions-that-support-shift-to-value-based-personalized-health-care-at-2017-bio-it-world-conference-300462121.html